Back to Search Start Over

Stability-indicating HPLC for remogliflozin, vildagliptin, and metformin: Method development, validation, and greenness.

Authors :
Acharya H
Kotadiya R
Source :
Annales pharmaceutiques francaises [Ann Pharm Fr] 2024 Nov; Vol. 82 (6), pp. 1071-1081. Date of Electronic Publication: 2024 Jun 28.
Publication Year :
2024

Abstract

Objective: The present work represents a reverse-phase high-performance liquid chromatography method in addition to stability studies for sequential estimation of remogliflozin etabonate, vildagliptin, and metformin HCl in tablet formulation.<br />Method: The mentioned method utilizes a Phenomenex Luna C18 column (250×4.6mm, 5μm). It consists of a column oven's temperature of 35°C. Mobile phase includes a mixture of 50% phosphate buffer (pH - 6.8) and 50% acetonitrile along with a flow rate of 0.8mL/min and 20minutes of run time. The injection volume was 20μL; 217nm is a detection wavelength, and a PDA detector is used for detection.<br />Results: The suggested technique was proven and validated per the ICH Q2 (R1) guideline. The combination was put under stress conditions that included acid, base, thermal, photolytic, and oxidative degradation. The combination was considerably degraded under oxidative, acidic, and basic circumstances for deterioration, and the degradation results were accurately identified from the observed peaks, demonstrating the method's effectiveness in detecting stability.<br />Conclusion: The technique was quick, precise, sensitive, and accurate; as a result, it may be used in quality control laboratories and the pharmaceutical industry for routine quality monitoring of tablets containing all three medications.<br /> (Copyright © 2024 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.)

Details

Language :
English
ISSN :
0003-4509
Volume :
82
Issue :
6
Database :
MEDLINE
Journal :
Annales pharmaceutiques francaises
Publication Type :
Academic Journal
Accession number :
38945392
Full Text :
https://doi.org/10.1016/j.pharma.2024.06.006